Although additional validation studies using corroborated clinical samples from IGF-1R-targeted therapies must be performed, our current study reveals malignant progression of tumours in the face of an IGF-1R blockade through IGF-2 secretion in the TME. This evidence concerns the gene IGF2 and neoplasm.